Product Data Sheet

CBP/p300-IN-19 hydrochloride

Cat. No.: HY-146277A CAS No.: 2592638-14-5 Molecular Formula: $C_{30}H_{28}CIN_3O_3$

Molecular Weight: 514.01

Target: Histone Acetyltransferase

Pathway: **Epigenetics**

Storage: Please store the product under the recommended conditions in the Certificate of

BIOLOGICAL ACTIVITY

Description CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 hydrochloride shows antitumor activity^[1].

IC₅₀ & Target Myst3 p300-HAT CBP-HAT **PCAF** $>100 \mu M (IC_{50})$ $1.4 \, \mu M \, (IC_{50})$ $2.2 \, \mu M \, (IC_{50})$ >100 µM (IC₅₀)

In Vitro CBP/p300-IN-19 hydrochloride (compound 29) shows antiproliferative activity with EC₅₀s of 5.3, 8.5, 6.2, 4.4, 1.2, 4.3, 3.6, 8.7,

6.4 μM for MCF-7, MDA-MB231, LNCaP, PC-3, PANC-1, MDA-PANC-28, Molm-13, MV4;11, RPMI-8226 cells, respectively^[1]. CBP/p300-IN-19 hydrochloride (0, 5, 10 µM; 12 h) dose-dependenly inhibits the acetylation of H3K18, H3K9 and K27^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	Kasumi-1 leukemia cells
Concentration:	0, 5, 10 μΜ
Incubation Time:	12 h
Result:	Dose-dependently inhibited the acetylation of H3K18, H3K9 and K27.

REFERENCES

[1]. Nie S, et al. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP. Eur J Med Chem. 2022 Jul 5;237:114407.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com